Brief: Medicenna Presents Promising Preclinical Data On IL-2 And IL-13 Superkines At The EORTC-NCI-AACR Annual Meeting

Medicenna Therapeutics

26/10/2020 12:22

Oct 26 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA PRESENTS PROMISING PRECLINICAL DATA ON IL-2 AND
IL-13
SUPERKINES AT THE EORTC-NCI-AACR ANNUAL MEETING
    * MEDICENNA THERAPEUTICS CORP - MONOTHERAPY AND COMBINATION
STUDIES CONTINUE TO DEMONSTRATE BEST-IN-CLASS POTENTIAL OF
MDNA11
    * MEDICENNA THERAPEUTICS - BISPECIFIC IL-2/IL-13 SUPERKINE
DEMONSTRATES POTENTIAL TO TREAT IMMUNOLOGICALLY "COLD" TUMORS
    * MEDICENNA THERAPEUTICS - EXPECTS TO DECLARE A LEAD
CANDIDATE FOR
ITS BISPECIFIC SUPERKINE PROGRAM IN 2021
    * MEDICENNA THERAPEUTICS - EXPECTS TO INITIATE A PHASE 1
CLINICAL
TRIAL WITH MDNA11 IN MID-2021

Source text for Eikon:  ID:nGNX5r3Klj 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))